NASDAQ:ATXI Avenue Therapeutics (ATXI) Stock Price, News & Analysis $0.50 0.00 (0.00%) As of 09/24/2026 02:47 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC Filings About Avenue Therapeutics Stock (NASDAQ:ATXI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Avenue Therapeutics alerts:Sign Up Key Stats Today's Range$0.40▼$0.6850-Day Range$0.25▼$0.8252-Week Range$0.15▼$0.97Volume9,236 shsAverage Volume6,805 shsMarket Capitalization$1.65 millionP/E Ratio0.03Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for acute pain and other central nervous system conditions. The company is a subsidiary of Fortress Biotech, Inc. and has historically concentrated its efforts on hospital-based treatments that address unmet medical needs. Avenue’s lead product candidate is an intravenous formulation of tramadol intended to manage acute postoperative pain in adults who require an opioid analgesic. The product is designed to provide healthcare professionals with an intravenous option for patients who cannot take medication orally. Avenue has advanced the candidate through clinical development and has worked with the U.S. Food and Drug Administration on its new drug application. The company’s activities have primarily been focused on the United States, including clinical development and regulatory work for its lead candidate. Avenue Therapeutics was established in 2015 and became a publicly traded company through a business combination with Fortress Biotech. Its management has included executives with backgrounds in pharmaceutical development, regulatory affairs and the commercialization of specialty medicines.AI Generated. May Contain Errors. Read More Receive ATXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATXI Stock News HeadlinesAvenue Therapeutics Inc.February 10, 2026 | barrons.comAvenue Therapeutics announces Baergic Bio acquisition by AxsomeNovember 6, 2025 | msn.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.September 25 at 1:00 AM | Altimetry (Ad)Avenue Therapeutics Reports Positive Earnings Amid ChallengesAugust 22, 2025 | msn.comUniversity Avenue will be closed for repair due to a sinkhole in MorgantownJuly 20, 2025 | msn.com17-year-old dies from gunshot wound near Colley Avenue, police sayJuly 20, 2025 | msn.comCrash involving a fire engine reported on Tennessee Avenue in Bond HillJuly 20, 2025 | msn.comKatipunan Avenue now passable after billboard collapse forces temporary closureJuly 20, 2025 | msn.comSee More Headlines ATXI Stock Analysis - Frequently Asked Questions How have ATXI shares performed this year? Avenue Therapeutics' stock was trading at $0.6802 on January 1st, 2026. Since then, ATXI shares have decreased by 26.5% and is now trading at $0.50. How were Avenue Therapeutics' earnings last quarter? Avenue Therapeutics, Inc. (NASDAQ:ATXI) posted its earnings results on Friday, August, 9th. The company reported ($6.43) earnings per share for the quarter, missing the consensus estimate of ($1.05) by $5.38. When did Avenue Therapeutics' stock split? Avenue Therapeutics shares reverse split on the morning of Friday, April 26th 2024.The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Avenue Therapeutics IPO? Avenue Therapeutics (ATXI) raised $30 million in an initial public offering on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager. How do I buy shares of Avenue Therapeutics? Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avenue Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avenue Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), GE Aerospace (GE), CrowdStrike (CRWD) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings8/09/2024Today9/25/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ATXI CIK1644963 Webwww.avenuetx.com Phone(781) 652-4500FaxN/AEmployees4Year Founded2015Profitability EPS (Trailing Twelve Months)($0.85) Trailing P/E Ratio0.03 Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-471.57% Return on Assets-296.50% Debt Debt-to-Equity RatioN/A Current Ratio2.70 Quick Ratio2.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book0.26Miscellaneous Outstanding Shares3,295,000Free Float2,017,000Market Cap$1.65 million OptionableNot Optionable Beta-0.18 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ATXI) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
